cyrilzakka/clinical-trials huggingface dataset:
An Exploration of the Relationship Between Chronic Pain and Suicide Attempt Among Veterans

The purpose of this study is to explore the relationship between attempted and/or completed suicide and reported experience of chronic pain among an adult veteran population. Specific aims include a) examining the experience of chronic pain between patients who have either attempted and/or completed suicide, non-suicide attempt mental health patients, and non-mental health chronic pain patients and b) determining possible differences in reported experiences of chronic pain based on mental and physical diagnoses, age, gender, ethnicity, occupation, and patient's recorded perceptions of depression and/or quality of life. As articulated in the Amendment approved on June 13, 2008, additional areas of interest include histories of neurological disease (e.g. traumatic brain injury) and/or mental health diagnoses. History of both neurologic disease and mental health diagnoses will also be identified by chart review (per approval obtained June 13, 2008). As such this study will also compare differences (e.g., mental health, neurological disease) between veterans who have history of a suicide attempt, completion, or a lifetime history of suicidality and matched control veterans without a history of suicide attempts, completions, or lifetime history of suicide. The relationship between suicidal behavior, attempted/completed suicide, and reported Post Traumatic Stress Disorder (PTSD) symptoms among an adult veteran population is also of interest. Additionally, this data set will be used to complete a validation study regarding the Self-Directed Violence Classification System (SDVCS). Specifically, relevant information in subject chart notes regarding self-directed violence (SDV) will be used to categorize thoughts and behaviors according to the SDVCS.


Eligibility Criteria:
Inclusion Criteria:

* Over the age of 18
* Record of a suicide attempt or completion between October 2004 and February 2006

Exclusion Criteria:

* For cases: upon chart review, no record of a suicide attempt or completion within the specified time frame
Cortical Activation During Walking in Stroke

After stroke, damage to one cerebral hemisphere disrupts the normal balance of activity between the two hemispheres. The affected hemisphere typically exhibits reduced excitability, whereas the unaffected side may demonstrate increased excitability. This phenomenon, referred to as interhemispheric imbalance, further inhibits activity in the affected hemisphere, thereby restricting motor recovery. According to the interhemispheric competition model, enhancing excitability in the affected hemisphere and/or suppressing excitability in the unaffected hemisphere may contribute to the improvement of motor function in individuals with stroke. Furthermore, as motor function recovers, the balance of interhemispheric activation in motor-related cortical areas undergoes corresponding changes. Previous studies have shown that treadmill training enhances the excitability of the primary motor cortex in both hemispheres of stroke patients, as well as increases excitability across multiple cortical and subcortical regions in both hemispheres. However, it remains unclear whether treadmill training can normalize the interhemispheric imbalance in stroke patients. Additionally, the effects of forward and backward walking on the activity of motor-related brain regions in individuals with stroke are still unclear. Therefore, this cross-sectional study aims to investigate the changes in motor-related brain activity during forward walking and backward walking in individuals with chronic stroke.


Eligibility Criteria:
Inclusion Criteria:

* ≥ 6 months after the diagnosis of stroke
* Independent walking over at least 7m with or without a walking aid
* Mini-mental state examination score ≥ 24

Exclusion Criteria:

* Had difficulty in backward walking
* Any neuromuscular disorders history
* With visual or auditory disorders
* Unstable cardiac status or uncontrolled hypertension
* Any musculoskeletal disorders that would affect walking ability
Calcitonin Level and New-onset of Post-Operative Atrial Fibrillation

Post-operative atrial fibrillation (POAF) is one of the common complicaiton following cardiac surgery, occurring in approximately 20%-40% patients. Although POAF is associated with longer hospital stays, most POAF is short lived and resolves in the 2-4 days afer cardiac surgery.

However, a recent meta-analysis showed significant increases in 1,5, and 10 year mortality in POAF patients (odds ratio:1.60, 2.60, 1.51;95% confidence intervals: 1.52 to 1.68, 2.00 to 3.38, 1.43 to 1.60;P \<0.0001), the combined adjusted risk of death (16 studies, n =84,295) was also significantly increased in patients with POAF (hazard ratio: 1.25;95% confidence interval: 1.2-1.3;P \< 0.0001).

These data highlight the need to understand better the underlying mechanism of POAF. A latest research in Nature reported levels of circulating calcitonin (CT), which is the main risk factor for atrial fibrillation (AF). Global disruption of CT receptor signalling in mice causes atrial fibrosis and increases susceptibility to AF.

Here we will explore the relationship between CT and POAF.


Eligibility Criteria:
Inclusion Criteria:

* 1. Clinical diagnosis of no history of atrial fibrillation/flutter;
* 2. Heart rate ≥50 beats/min;
* 3. EF \> 40%;
* 4. No history of emergency cardiac surgery in our hospital;
* 5. Participate voluntarily and sign the informed consent, and can accept the follow-up of more than 2 years.

Exclusion Criteria:

* 1. Atrial fibrillation/flutter;
* 2. Left atrial diameter \>5.5cm;
* 3. Previous cardiac surgery or emergency surgery (\<12h);
* 4. Sick sinus node syndrome;
* 5. Ventricular preexcitation or preexcitation syndrome;
* 6. Second degree or above atrioventricular block;
* 7.Myocardial infarction occurred within 7 days;
* 8. Infection, sepsis, rheumatic or inflammatory diseases;
* 9. Abnormal liver and kidney function (three times higher than the upper limit of normal);
* 10. Uncontrolled hyperthyroidism, severe obstructive sleep apnea, and acute alcoholism;
* 11. Any ischemic events (stroke or TIA) that occurred 180 days before the participant signed the informed consent, or any known unresolved complications from previous stroke/TIA;Thrombosis;
* 12. Patients with other diseases requiring radiotherapy, chemotherapy and long-term hormone therapy;
* 13. Patients' life expectancy makes it unlikely that follow-up will be completed;
* 14. Participate in, or are expected to participate in, other clinical trials of any drugs, devices or biologics during the study period;
* 15. Patients with contraindications to dynamic electrocardiogram;
* 16. Patients who are unwilling or unable to fully comply with study procedures and follow-up.
The Efficacy of Treatment for Helicobacter Pylori Infection in Preschooler by Yoghurt With LG21

The goal of this randomized, open-label, interventional trial is to study the efficacy of treatment for Helicobacter Pylori Infection in Preschooler aged 4-6 by Meiji Yoghurt with LG21. The main question it aims to answer is:

- whether the treatment by Meiji Yoghurt LG21 is effective by stool antigen (HpSA) test

140 qualified participants will be enrolled and randomized into 2 groups of the same size (product study group and blank control group). Participants of the product study group will need to eat assigned Meiji Yoghurt for 12 weeks, one bottle each day, while participants of the blank control group won't receive any intervention during the study. Four visits will be made for all participants, and relevant clinical data will be captured and recorded into CTMS (Clinical Trial Management System) for statistical analysis and reporting.


Eligibility Criteria:
Inclusion Criteria:

* Preschooler aged 4-6 years
* H. pylori positive
* Drink milk or milk beverages regularly (more than three times a week) before joining the study
* ICF signed
* Parents or guardians agree not to participate in other interventional clinical studies during this study

Exclusion Criteria:

* Has potential metabolic class or chronic disease
* Use of antibiotics within 7 days before randomization (as judged by the trial responsible physician)
* People who have been treated for eradication of Helicobacter pylori
* Pharmaceuticals, medicinal skin care products (medical external products) and health foods that may affect gastric symptoms have been commonly used since more than one month ago
* Already under digestive system treatment
* Has lactose intolerance or protein allergy
* Those whose families had plans to leave Jinhua City during the study period
* Fails to comply with the provisions of the protocol
* Those who are deemed unsuitable as subjects by the physician
Cycling Intervention on Symptoms of Patients With Knee Osteoarthritis

This study is designed to determine the effect of a cycling training program which modulates frontal and sagittal plane knee joint loading with graded increases of Q-Factor and cycling workrate in persons with symptomatic knee osteoarthritis.

The knee joint is one of the most common joints affected by osteoarthritis, and knee osteoarthritis is primarily observed in the medial compartment. This is in part attributable to the increased load experienced by the medial compartment during level walking. Patients with symptomatic knee osteoarthritis exhibit altered gait mechanics; namely a reduced loading response knee extension moment and an increased internal knee abduction moment. As a surrogate measure for medial compartment joint loading, loading response knee abduction moment in level walking has been shown to increase with the severity of knee osteoarthritis.

Recent gait modification research has shown that increased step-width decreases peak Knee abduction moment for persons with knee osteoarthritis. The inter-pedal width of a bicycle or cycle ergometer, known as Q-Factor, is analogous in cycling to step-width in gait. In contrast to gait, increased Q-Factor has been shown to increase the knee abduction moment during stationary cycling. Modulating sagittal and frontal plane loading of the knee in a graded manner during cycling may promote healthy adaptation to muscle weakness and pain. This adaptation may be manifest through restoration of altered knee joint biomechanics (knee extension moment, knee abduction moment), which, in turn, may also provide benefit to gait mechanics.

Eligibility Criteria:
Inclusion Criteria:

* Men and Women between the ages of 50 and 75 years old.
* Diagnosed with medial compartment tibiofemoral osteoarthritis in one of their knees.
* Be able to walk unaided for at least 25 consecutive minutes.
* Present with knee pain for at least 6 months occurring on a majority of the days in the month, or on most days (more than or equal to 4 of 7 days in a week) in one or both knees for at least 4 months.
* Osteophytes on knee x-rays.
* Grade 2 or higher out of a maximum of 4 on a modified Kellgren/Lawrence grade on the knee radiograph.

Exclusion Criteria:

* Initial Visual Analog Scale pain scores greater than 7.
* Diagnosed osteoarthritis of ankles, hips, or symptomatic osteoarthritis of the spine.
* Arthroplasty of any other lower extremity joint.
* BMI value greater than 40 kg/m2.
* Any major lower extremity injury in the past 6 months.
* Systemic Inflammatory Arthritis.
* Systemic Pain Conditions.
* Neurological Conditions that impact gait or cycling.
* Pregnant or Nursing Women.
* Major cardiovascular disease with an exercise limitation prescribed by a physician.
* Steroid injection at the knee within the previous 3 months.
Self-assured Parents - a Parenting Support Program for Immigrant Parents With Teenage Children Living in Deprived Areas

Parents have the primary responsibility for child socialization and development, but not all parents have the same possibilities to promote their children's positive development. Immigrant parents living in deprived areas often worry about their children's safety and future, at the same time as they have difficulties facilitating the best development potential for their children. Social services can help parents and their children to attain more promising developmental outcomes through focus on early preventive parenting support efforts, but these efforts need to be culturally tailored for the best possible results. For this reason, social services in the municipality of Örebro developed a culturally sensitive parenting support program aimed at immigrant parents living in deprived areas, who are worried that their children (age 12-18) engage in or will be exposed to harmful environments.

The Self-Assured Parenting Program (SAP) offers support to these parents by building on protective factors and strengthening parents in their parenting through focus on parenting competence and parent-child communication.

The purpose of SAP is to increase parents' self-confidence and communication between parents and their teenagers as well as to reduce parents' worries through activities that have a clear focus on empowerment and knowledge of child development. This multi-design project aims to test the implementation and effect of TF in Örebro and other Swedish municipalities with similar problems through observation, interviews with parents and groupleaders/managers as well as longitudinal effect measurements of parenting competence, parent-child communication and worries about their children's psychosocial development. This project will allow a partnership between social workers and researchers to be formed in order to generate practice-based evidence about implementation of support to deprived parents, which can be used in the context of everyday social service practice.


Eligibility Criteria:
Inclusion Criteria:

* parents of adolescent Children
* immigrant background

Exclusion Criteria:

* parents of younger Children
* Swedish background
Efficient Postoperative Pain Management With Multimodal IV

Postoperative pain remains a prevalent concern despite ongoing improvements in surgical methods and pain management strategies. Opioids, while commonly prescribed, frequently lead to undesirable side effects. Epidural analgesia, though a viable option, carries its risks and complications. Recent research indicates that combining intravenous lidocaine and ketamine can significantly alleviate postoperative pain and decrease the reliance on opioids within the initial 24 hours following surgery. This approach offers a promising alternative with minimal additional adverse effects, suggesting a potential shift in pain management practices.


Eligibility Criteria:
Inclusion Criteria:

* Patients were assigned for surgical intervention;
* Patients of ASA grade I-III;
* Patients were free of exclusion criteria;

Exclusion Criteria:

* Patients who are not in ASA grade I-III;
* Patients who had uncontrolled hypertension and/or diabetes mellitus;
* Patients who had uncompensated cardiac, renal, or hepatic diseases;
* Patients with coagulopathy, spinal deformity, allergy, or contraindication for the used drugs;
* Patients who refused to sign the informed consent were excluded from the study.
Metal Ion Levels in Stryker Trident II Tritanium System with Modular Dual Mobility (MDM) Liner, Ceramic Head, and SecurFit Advanced Stems

Metal Ions levels of cobalt, chromium, and titanium in 40 patients preoperatively and at least 1 year status post total hip replacement with the Trident II Tritatnium system using an MDM liner and ceramic head. Are cobalt, chromium, and titanium levels in patients who undergo a total hip replacement with a Trident II Tritanium system, MDM liner, and ceramic head normal one year after surgery? Investigators expect to find normal levels of metal ions (cobalt, chromium, and titanium) after total hip replacement using Trident II Tritanium cups with an MDM liner and a ceramic head. The primary outcome (PO) is blood metal ion levels of cobalt, chromium, and titanium (concentration of metal ions in blood). Blood will be drawn in the 3rd Floor West of the Main Building, and then tested for metal ions in the Hospital for Special Surgery laboratory. The bloods will be drawn at a preoperative visit and at a one year visit.


Eligibility Criteria:
Inclusion Criteria:

1. Patients who will be undergoing a total hip replacement with a Stryker Trident II cup
2. Patients have signed an Institutional Review Board (IRB) approved consent form
3. Patient is 21-80
4. Patient has a diagnosis of Non-Inflammatory Degenerative Joint Disease
5. Patient is willing and able to comply with postoperative scheduled clinical evaluations.

Exclusion Criteria:

1. Patients who have not been consented as part of the Collaborative Orthopaedic Replacement Registry (CORRe) database
2. Patients with other joint replacements (shoulder/knee)
3. Patients with bilateral hip replacements
4. Prisoners
5. International Patients
Safety Study for the Use of Rapamycin in Children with Familial Adenomatous Polyposis

The hypothesize of this research is that rapamycin is effective and well-tolerated in teenagers with familial adenomatous polyposis (FAP). Rapamycin could be effective in blocking the formation of adenomas and/or their evolution by decreasing their size and number. Researchers aim to assess the safety profile of rapamycin in FAP adolescents using a 2 low dose regimen.

FAP is a rare genetic disease linked to mutations of APC gene. Adenomatous polyps appear around the age of 10 and will evolve into colic adenocarcinoma. To date, there is no effective treatment; 100% of patients will develop colorectal cancer before 40 years. This risk is addressed by regular colonoscopy monitoring, in order to propose a timely prophylactic colectomy.

Rapamycin (sirolimus) is a drug that targets the mTOR (mammalian target of rapamycin) protein involved in the PI3K-Akt signalling pathway downstream of PI3K. There are interactions between the PI3K-Akt pathway and the Wnt/APC/-catenin pathway that is hyperactivated in FAP. Rapamycin was used out of indication with efficacy and good tolerance in 2 adolescents whose parents had refused colectomy. Researchers recently demonstrated its effectiveness in a child with very severe juvenile polyposis. Data are also available in animals, but no proof-of-concept studies have been conducted in humans.

In France, Rapamycin use is allowed in adults with kidney transplantation and pulmonary lymphangioleiomyomatosis. However, it is used on children over the market. According to the literature and the field experience, the hypothesize is that a through level of 3-8 ng/ml should be effective in children with FAP, with a lower rate of adverse events.

Eligibility Criteria:
Inclusion Criteria:

* Children aged 12 to 17 at time of inclusion.
* Patients with colonoscopy for diagnosis or follow-up of FAP.
* ≥ 5 polyps (\> 2 mm) at initial colonoscopy (V1).
* Free and informed consent, signed by both holders of parental authority/legal representative, with the accord of the minor patient.
* Affiliated with a social security scheme.
* Patients of childbearing potential must agree to the use of a method of contraception during the study.

Exclusion Criteria:

* Inability to understand the nature and goals of the study and/or communication difficulties observed by the investigator.
* Contraindication to performing a colonoscopy.
* \< 5 polyps (\>2 mm) registered during initial colonoscopy (V1).
* Advanced disease with high-grade dysplasia adenoma or even adenocarcinoma in situ that should required colectomy
* Signs of primary tuberculosis infection or respiratory infection
* Any other medical or psychological condition deemed incompatible with the proper conduct of the study according to the investigator.
* Contraindications to rapamycin use
* Participation in other biomedical research
* Deprivation of liberty of the legal guardians by judicial or administrative decision.
* Pregnancy, breastfeeding
TherApy in stabLe Coronary Artery dIsease Patients According to Clinical GuideliNes (ALIGN)

The aim of this prospective cohort study is to assess the quality of therapy in patients with stable ischemic heart disease (IHD) who had never applied for specialized medical care for the last 3 years and try to accord their treatment with current clinical guidelines.

The purpose of this study is to assess the quality of therapy in patients having come for the first time consultation to the specialized cardiology department of the scientific research centre within the PROFILE registry and to try to correct therapy according to current clinical guidelines paying particular attention to reaching target blood pressure (BP), low-density lipoprotein cholesterol (LDL-C), glycosylated haemoglobin - HbA1c (in patients with diabetes mellitus) levels, improving exercise tolerance and quality of life.

The first visit (V0) is an inclusion in the study. During this visit, an attempt to correct or start (if it had not been started before) antiplatelet, hypolipidemic, antihypertensive and antianginal therapy will be made.

The second visit (V1) is planned for each patient three months after the first visit (V0). During the second visit number of patients who reached target levels of BP, LDL-C, frequency of angina attacks will be assessed. If necessary, correction of therapy will also be made.

The third visit (V2) is planned for each patient one year after the first visit (V0). During the third visit reaching target BP, LDL-C levels, frequency of angina attacks will be assessed. If necessary, therapy correction will be recommended.

The last visit - telephone contact with patients - is expected in 2 years after the first visit. During that visit it is planned to assess life status, complications and current medical treatment.

Eligibility Criteria:
Inclusion Criteria:

All patients with documented IHD having consequentially come for the first time for consultation to the specialized cardiology department of the scientific research center from December 31, 2017 to December 31, 2022.

Documented IHD:

1. Positive results of the angina questionnaire (typical angina)
2. Positive exercise electrocardiography or stress echocardiography, plus one of the following criteria:

   * ischemia documented by scintigraphy study
   * invasive coronary angiography data (stenosis of at least 75% in at least one main coronary artery)
   * previous coronary revascularization (percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG))
   * previous myocardial infarction
   * patients who had elective PCI or CABG

Exclusion Criteria:

* Patients with acute IHD (less than 30 days since the last ischemic event with or without invasive procedures for the treatment of the event)
* Patients' refuse to follow the study's graphic of doctors' visits